Michele Prisciandaro
European Neuroendocrine Tumor Society(DE)Fondazione IRCCS Istituto Nazionale dei Tumori(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Gastric Cancer Management and Outcomes, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives(2019)239 cited
- → Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma(2018)196 cited
- → Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial(2022)123 cited
- → RET fusions in a small subset of advanced colorectal cancers at risk of being neglected(2018)112 cited
- → Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study(2017)108 cited
- → INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).(2023)91 cited
- → The Landscape of Actionable Gene Fusions in Colorectal Cancer(2019)63 cited
- → Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO(2024)60 cited
- → The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer(2018)53 cited
- → TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study(2021)51 cited